INS and metabolic syndrome: In a metabolic syndrome model, the GLP-1 receptor agonist exendin-4 was given to hyperglycemia mice, resulting in sustained plasma glucose reduction, weight loss, and enhances insulin sensitivity over multiple weeks of treatment (Young et al., 1999).